Adjuvant Pembrolizumab Significantly Improves DFS in Renal Cell Carcinoma
Pembrolizumab was associated with a 32% reduction in the risk of disease recurrence or death compared with placebo as an adjuvant treatment for patients with clear cell renal cell carcinoma.